BioCryst Wins FDA Approval for ORLADEYO 150 mg Oral Pellets, Extending a Once-Daily Option for HAE Patients 12+
Market Chameleon (Wed, 21-Oct 8:14 AM)
BioCryst wins FDA nod for Orladeyo oral pellets
at seekingalpha.com (Wed, 21-Oct 11:04 AM)
Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM), BioMarin Pharmaceutical (BMRN) and BioCryst (BCRX)
at www.tipranks.com (Wed, 21-Oct 9:01 AM)
BioCryst Raises 2026 Revenue Outlook After Strong Q2—ORLADEYO Growth and Pipeline Advances Highlight Momentum
Market Chameleon (Wed, 5-Aug 7:37 AM)
